Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HHV-6 associated diseases are one of the major factors on higher early CNS complications in CB recipients than in those of BM/PBSC.
Kageyama K, Uchida N, Yamamoto H, Takagi S, Ebihara M, Yuasa M, Kaji D, Nishida A, Ishiwata K, Yamamoto G, Asano-Mori Y, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. Kageyama K, et al. Among authors: wake a. Bone Marrow Transplant. 2021 Mar;56(3):686-688. doi: 10.1038/s41409-020-01028-5. Epub 2020 Aug 11. Bone Marrow Transplant. 2021. PMID: 32782352 No abstract available.
Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone.
Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, Yamamoto H, Kato D, Matsuno N, Masuoka K, Araoka H, Asano-Mori Y, Izutsu K, Makino S, Yoneyama A, Taniguchi S. Uchida N, et al. Among authors: wake a. Transplantation. 2011 Aug 15;92(3):366-71. doi: 10.1097/TP.0b013e318223d7ac. Transplantation. 2011. PMID: 21677598 Clinical Trial.
Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies.
Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Yamamoto H, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2014 Oct;20(10):1634-40. doi: 10.1016/j.bbmt.2014.06.024. Epub 2014 Jun 24. Biol Blood Marrow Transplant. 2014. PMID: 24972251 Free article.
Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation.
Yuasa M, Yamamoto H, Kageyama K, Kaji D, Taya Y, Takagi S, Yamamoto G, Asano-Mori Y, Wake A, Yoneyama A, Makino S, Uchida N, Taniguchi S. Yuasa M, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2020 Sep;26(9):1689-1696. doi: 10.1016/j.bbmt.2020.05.018. Epub 2020 Jun 4. Biol Blood Marrow Transplant. 2020. PMID: 32505808 Free article.
Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
Yuasa M, Yamamoto H, Mitsuki T, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Wake A, Koike Y, Makino S, Uchida N, Taniguchi S. Yuasa M, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2020 Dec;26(12):2262-2270. doi: 10.1016/j.bbmt.2020.08.026. Epub 2020 Aug 29. Biol Blood Marrow Transplant. 2020. PMID: 32871257 Free article.
The impact of graft cell source on bloodstream infection in the first 100 days after allogeneic hematopoietic cell transplantation.
Takagi S, Ogura S, Araoka H, Uchida N, Mitsuki T, Yuasa M, Kageyama K, Kaji D, Taya Y, Nishida A, Kimura M, Ishiwata K, Yamamoto H, Yamamoto G, Asano-Mori Y, Koike Y, Izutsu K, Wake A, Makino S, Yoneyama A, Taniguchi S. Takagi S, et al. Among authors: wake a. Bone Marrow Transplant. 2021 Jul;56(7):1625-1634. doi: 10.1038/s41409-021-01229-6. Epub 2021 Feb 19. Bone Marrow Transplant. 2021. PMID: 33608659
Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients.
Narimatsu H, Matsumura T, Kami M, Miyakoshi S, Kusumi E, Takagi S, Miura Y, Kato D, Inokuchi C, Myojo T, Kishi Y, Murashige N, Yuji K, Masuoka K, Yoneyama A, Wake A, Morinaga S, Kanda Y, Taniguchi S. Narimatsu H, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2005 Jun;11(6):429-36. doi: 10.1016/j.bbmt.2005.01.010. Biol Blood Marrow Transplant. 2005. PMID: 15931631 Free article.
Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.
Miyakoshi S, Kusumi E, Matsumura T, Hori A, Murashige N, Hamaki T, Yuji K, Uchida N, Masuoka K, Wake A, Kanda Y, Kami M, Tanaka Y, Taniguchi S. Miyakoshi S, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2007 Jul;13(7):771-7. doi: 10.1016/j.bbmt.2007.02.012. Biol Blood Marrow Transplant. 2007. PMID: 17580255 Free article.
Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
Miyakoshi S, Kami M, Tanimoto T, Yamaguchi T, Narimatsu H, Kusumi E, Matsumura T, Takagi S, Kato D, Kishi Y, Murashige N, Yuji K, Uchida N, Masuoka K, Wake A, Taniguchi S. Miyakoshi S, et al. Among authors: wake a. Transplantation. 2007 Aug 15;84(3):316-22. doi: 10.1097/01.tp.0000269796.23593.16. Transplantation. 2007. PMID: 17700155 Clinical Trial.
Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.
Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, Matsumura T, Seo S, Matsuno N, Masuoka K, Kusumi E, Yuji K, Miyakoshi S, Matsuzaki M, Yoneyama A, Taniguchi S. Uchida N, et al. Among authors: wake a. Biol Blood Marrow Transplant. 2008 May;14(5):583-90. doi: 10.1016/j.bbmt.2008.03.003. Biol Blood Marrow Transplant. 2008. PMID: 18410901 Free article. Clinical Trial.
242 results